Diabetes News and Research

Latest Diabetes News and Research

PHT signs 11 new trials in second-quarter 2010

PHT Corporation featured scientific education as a key focus during its record-breaking second fiscal quarter of 2010. PHT is the global innovator in ePRO (electronic patient reported outcome) and PRO (patient reported outcome) solutions that maximize clinical data management by incorporating the world's best digital diaries in eClinical trials.

5 Aug 2010

Merck's two pivotal boceprevir Phase III registration studies for chronic HCV meet primary endpoint

Merck reported that two pivotal Phase III registration studies for boceprevir, its investigational oral hepatitis C protease inhibitor, have been completed and met the primary endpoints: in both studies in patients with chronic hepatitis C virus (HCV) genotype 1 infection, the addition of boceprevir to treatment with PEGINTRON® and REBETOL® significantly increased the number of patients who achieved sustained virologic response, compared to control groups that received Peg/riba plus placebo.

5 Aug 2010

Study finds proximal prayer may help another person's healing

Findings reported today from a new international study of healing prayer suggest that prayer for another person's healing just might help especially if the one praying is physically near the person being prayed for.Candy Gunther Brown, an associate professor in the Department of Religious Studies at Indiana University Bloomington, led the study of "proximal intercessory prayer" for healing. It is available online today and will be published in the September 2010 issue of the Southern Medical Journal.

5 Aug 2010

Genzyme, Isis announce results of two mipomersen phase 3 studies

Genzyme Corp. and Isis Pharmaceuticals Inc. today announced results of two phase 3 studies of mipomersen in patients who had high cholesterol levels while on maximally tolerated lipid-lowering therapy. In the study of patients with severe hypercholesterolemia, mipomersen reduced LDL-C, the primary endpoint, by 36 percent compared with a 13 percent increase for placebo.

5 Aug 2010

Penn. effort fades to override cuts to family planning; Ill. faces budget cuts to health care; Mich. focuses on high cost of chronic disease

The Philadelphia Inquirer: "As two Democratic state lawmakers initiated a campaign to override the governor's veto of $7.5 million for family-planning health centers, six Republican state senators who previously voted to restore the funding reversed course, most likely ending any hopes of restoring the money. Democrats would need at least four Republican votes for an override in the Senate, which now appears unlikely.

5 Aug 2010

Amputation can be prevented when patients are treated by podiatric physicians: Study

Amputation, one of the most devastating and costly consequences of diabetes, can be prevented when patients are treated by podiatric physicians. That's the finding of a national, large-scale study co-authored by Dr. James Wrobel, DPM, MS, Associate Professor of Medicine at Rosalind Franklin University of Medicine and Science.

5 Aug 2010

Alnylam second-quarter revenues increase to $26.6 million

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, today reported its consolidated financial results for the second quarter ended June 30, 2010, and company highlights.

5 Aug 2010

Ferroportin levels are strong predictors of propensity for breast cancer recurrence: Study

A new study by researchers at Wake Forest University Baptist Medical Center (WFUBMC) may soon help to spare some women with breast cancer from having to undergo invasive and toxic treatments for their disease.

5 Aug 2010

Excess maternal weight gain predicts high birth weight: Research

Expectant mothers who gain large amounts of weight tend to give birth to heavier infants who are at higher risk for obesity later in life. But it's never been proven that this tendency results from the weight gain itself, rather than genetic or other factors that mother and baby share. A large population-based study from Children's Hospital Boston, looking at two or more pregnancies in the same mother, now provides evidence that excess maternal weight gain is a strong, independent predictor of high birth weight.

5 Aug 2010

Sigma-Aldrich, NHLBI and BU collaborate in atherosclerotic cardiovascular disease research

Sigma-Aldrich® today announced it has entered into an agreement with the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health, and Boston University (BU) to develop methods to measure several potential biomarkers of atherosclerotic cardiovascular disease (CVD) using plasma samples from the NHLBI's Framingham Heart Study (FHS), one of the most prestigious clinical studies in medicine. Funding for the project is provided by the NHLBI to Sigma-Aldrich under a research subaward agreement with BU.

5 Aug 2010

Scientist invents new approach to boost body's response to vaccinations

As the medical community searches for better vaccines and ways to deliver them, a University of Rochester scientist believes he has discovered a new approach to boosting the body's response to vaccinations.Richard P. Phipps, Ph.D., found that the same molecules used in drugs that treat diabetes also stimulate B cells in the immune system, pushing them to make antibodies for protection against invading microorganisms.

5 Aug 2010

FDA designates XOMA 052 orphan drug for Behcet's disease

XOMA Ltd., a leader in the discovery and development of therapeutic antibodies, announced that the U.S. Food and Drug Administration has designated XOMA 052, an antibody to interleukin-1 beta, an orphan drug for the treatment of Behcet's disease. As previously announced, the Committee for Orphan Medical Products of the European Medicines Agency has recommended the granting of orphan medicinal product designation for XOMA 052 for the same indication in the European Union.

5 Aug 2010

Roche inaugurates National Infusion Site Awareness Week to promote diabetis management

Roche Diabetes Care, makers of the ACCU-CHEK portfolio of diabetes management products and services, is pleased to announce the inaugural National Infusion Site Awareness Week, Aug. 30-Sept. 5. Roche made the announcement during the 37th annual American Association of Diabetes Educators (AADE) conference to highlight the important role that certified diabetes educators and other health care professionals play in promoting better site management for the 400,000 people in the United States with Type 1 diabetes who use an insulin pump.

5 Aug 2010

Pregnancy weight gain liked to childhood obesity: Study

Women who gain excessive weight during pregnancy have a greater chance their babies will be born too big. Scientists are trying to find whether this relationship of gaining too much weight by mother and baby is genetic and can predispose the child to be obese later in life.

4 Aug 2010

Research examines effects of orthostatic hypotension in adults, children

A simple variation to the tried and true method of checking blood pressure can reveal startling information about both older and younger persons, new research suggests.

4 Aug 2010

Targacept licenses Cornerstone technology for inflammatory disorders program

Targacept, Inc., a clinical-stage biopharmaceutical company developing novel NNR Therapeutics(TM), today announced that it has added to its program for inflammatory disorders by entering into an exclusive worldwide license agreement with Cornerstone Therapeutics Inc. The agreement grants Targacept rights to Cornerstone's NNR-based patents, as well as its library of preclinical compounds that act on the alpha7 or other nicotinic receptors.

4 Aug 2010

Contrave added to diet and exercise regimen can induce significant weight loss

Orexigen Therapeutics, Inc. announced the online publication of results from its COR-BMOD trial of Contrave (naltrexone SR/bupropion SR) in the journal Obesity. The COR-BMOD trial evaluated intensive behavior modification plus Contrave32 (32mg naltrexone sustained release (SR)/360mg bupropion SR) compared to BMOD plus placebo, in 793 overweight or obese patients.

4 Aug 2010

Study shows link between fructose and pancreatic cancer proliferation

Pancreatic cancers use the sugar fructose, very common in the Western diet, to activate a key cellular pathway that drives cell division, helping the cancer to grow more quickly, a study by researchers at UCLA's Jonsson Comprehensive Cancer Center has found.

4 Aug 2010

Arcelis immunotherapy effective in treating autoimmune diseases: Study

Argos Therapeutics today announced that its Arcelis immunotherapy targeted at diabetes demonstrated potential for preventing and treating the disease in non-obese diabetic (NOD) mice, according to a peer-reviewed article published in Molecular Therapy.

4 Aug 2010

DTB launches Don't Drop Mixtard 30 campaign to change Novo Nordisk's drug removal decision

Drug company Novo Nordisk's decision to pull its Mixtard 30 insulin drug from the UK could add 9 million to the NHS drugs bill in England alone, says an editorial in the Drug and Therapeutics Bulletin (DTB). The decision could also leave thousands of patients dependent on others to help them take their insulin, says DTB, which today launches its "Don't Drop Mixtard 30" campaign to convince the company to change its mind.

4 Aug 2010